Legend Biotech Corporation

Equities

LEGN

US52490G1022

Market Closed - Nasdaq Other stock markets 20:00:00 13/03/2026 GMT			5-day change	1st Jan Change
18.75 ^USD	-1.57%		-1.16%	-13.75%

03-11	Legend Biotech Shares Likely to Rebound in 2026 on Robust Fundamentals, RBC Says	MT
03-11	RBC Cuts Price Target on Legend Biotech to $62 From $66, Keeps Outperform Rating	MT

Transcript : Legend Biotech Corporation Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-09-2025 04

Published on 09/09/2025 at 10:20 pm BST - Modified on 09/10/2025 at 04:35 am BST

S&P Capital IQ

Presenter Speech
Terence Flynn (Analysts)

Great. Thanks for joining us, everybody. I'm Terence Flynn, Morgan Stanley's U.S. biopharma analyst. I'm very pleased to be hosting Legend today. From the

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Legend Biotech Corporation

03-11	Legend Biotech Shares Likely to Rebound in 2026 on Robust Fundamentals, RBC Says	MT
03-11	RBC Cuts Price Target on Legend Biotech to $62 From $66, Keeps Outperform Rating	MT
03-10	Legend Biotech Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
03-10	Legend Biotech Corporation, Q4 2025 Earnings Call, Mar 10, 2026
03-10	Legend Biotech Adjusted Q4 Earnings, Revenue Increase	MT
03-10	Earnings Flash (LEGN) Legend Biotech Corporation Reports Q4 Revenue $306.3M, vs. FactSet Est of $307.8M	MT
03-10	Earnings Flash (LEGN) Legend Biotech Corporation Posts Q4 Adjusted Net Income $0.01 per Share	MT
03-10	Earnings Flash (LEGN) Legend Biotech Posts Q4 Loss $0.08 a Share, vs. FactSet Est of $0.02 EPS	MT
02-23	Gilead to buy cancer therapy developer Arcellx for up to $7.8 billion	RE
02-12	Legend Biotech Shares Lower After Rothschild & Co Redburn Downgrade	MT
02-12	Rothschild & Co Redburn Downgrades Legend Biotech to Neutral From Buy	MT
02-06	Legend Biotech Corporation Announces Board and Audit Committee Changes, Effective February 2, 2026	CI
01-23	Legend Biotech Corporation Announces Changes to Board of Directors and Audit Committee, Effective January 20, 2026	CI
01-22	TD Cowen Downgrades Legend Biotech to Hold From Buy, Adjusts Price Target to $21 From $62	MT
01-22	Genscript Biotech Associate Books $555 Million in Q4 CARVYKTI Sales	MT